<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03726788</url>
  </required_header>
  <id_info>
    <org_study_id>RC-P0037</org_study_id>
    <nct_id>NCT03726788</nct_id>
  </id_info>
  <brief_title>Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis</brief_title>
  <acronym>TOXART</acronym>
  <official_title>Analysis of Antalgic Efficacy of an Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis by Perfusion MRI:a Superiority, Randomized, Controlled, Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lille Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lille Catholic University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We believe we can demonstrate a link between the analgesic action of intra-articular
      injection of botulinum toxin and synovial inflammation by Dynamic Contrast Enhancement (DCE)
      perfusion Magnetic Resonance Imaging (MRI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Knee osteoarthritis is one of the most common causes of joint pain and functional disability
      in the general population.

      Intra-articular infiltrations of corticoids are indicated for painful crisis especially if
      accompanied of effusion. However, this effect lasts only 2 weeks.

      Given the lack of effective long-term medical-infiltrative treatment, we believe that
      botulinum toxin type A could be used by its direct action on mediators of neuro-gene
      inflammation at the joint level and its indirect medullary action by retrograde migration.

      To date, 2 published randomized controlled trials and one unpublished Phase Ib clinical trial
      have shown that botulinum toxin injected intraarticularly improves pain and functionality in
      gonarthrosis.

      Dynamic Contrast Enhancement (DCE) Magnetic Resonance Imaging (MRI) demonstrated the
      correlation between synovial inflammation and pain in gonarthrosis in a cohort of 454
      subjects. It has also made it possible, via the monitoring of synovial inflammation, to
      demonstrate the efficacy of treatments in patients suffering from rheumatoid arthritis in the
      early phase, juvenile chronic arthritis or osteoarthritis.

      DCE MRI perfusion therefore appears here as the technique of choice to follow the evolution
      of synovial inflammation after botulinum toxin injection in patients with symptomatic
      gonarthrosis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only pharmacists and radiologists know the patient's randomizing arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Assesment of vascularization by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) according to the % Area Under the Curve (AUC) of perfusion value</measure>
    <time_frame>one month post-injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain analysis by the visual analogue scale (VAS)</measure>
    <time_frame>during the first 3 months after injection</time_frame>
    <description>Evolution kinetics of daily pain collected during the first 3 months post-injection allowing to deduce the onset and duration of analgesic efficacy in number of days. The pain VAS is a continuous scale comprised of a horizontal line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme: &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; (score of 100 [100‐mm scale])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint amplitude measured by goniometry</measure>
    <time_frame>at 1, 3, 6 month post-injection</time_frame>
    <description>To measure range of motion of the knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Ontario McMaster University Osteoarthritis (WOMAC) Index</measure>
    <time_frame>at 1, 3, 6 month post-injection</time_frame>
    <description>An arthritic pain scoring system ranging from 0-no pain/disability to 100-most severe pain/disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two minutes walk</measure>
    <time_frame>at 1, 3, 6 month post-injection</time_frame>
    <description>This test measure the distance walked in two minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of consumption of analgesics</measure>
    <time_frame>at 1, 3, 6 month post-injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of consumption of analgesics</measure>
    <time_frame>at 1, 3, 6 month post-injection</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Joint Diseases</condition>
  <condition>Knee</condition>
  <condition>Therapeutics</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type A 100U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one intra-articular injection in the painful knee 30 days after the inclusion visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type A 200U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one intra-articular injection in the painful knee 30 days after the inclusion visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone Hexacetonide 20 MG/ML</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one intra-articular injection in the painful knee 30 days after the inclusion visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A 100U</intervention_name>
    <description>one intra-articular injection of 100 U of botulinum toxin type A, diluted in 2 ml of 0.9% SSI</description>
    <arm_group_label>Botulinum Toxin Type A 100U</arm_group_label>
    <other_name>Botox 100 UNT Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A 200U</intervention_name>
    <description>one intra-articular injection of 200 U of botulinum toxin type A, diluted in 4 ml of 0.9% SSI</description>
    <arm_group_label>Botulinum Toxin Type A 200U</arm_group_label>
    <other_name>Botox 200 UNT Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Hexacetonide Inj Susp 20 MG/ML</intervention_name>
    <description>one intra-articular injection of 2 ml Triamcinolone Hexacetonide</description>
    <arm_group_label>Triamcinolone Hexacetonide 20 MG/ML</arm_group_label>
    <other_name>HEXATRIONE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presenting gonarthrosis of degenerative origin, Kellgren/Lawrence Radiological Stage I
             to III, with a maturity of more than 18 months

          -  With pain intensity greater than or equal to 50/100 on an VAS

          -  In case of bilateral gonarthrosis, the VAS of the contralateral knee must be less than
             or equal to 30/100

          -  Presenting a failure of conventional per os treatments (non-steroidal
             anti-inflammatory drugs, analgesics)

          -  Affiliated with a social security scheme

          -  For women of childbearing age:

               -  effective contraception for the duration of the study

        Exclusion Criteria:

          -  Patient presenting at the time of the inclusion visit: an inflammatory attack, septic
             or inflammatory arthritis, a generalized infectious episode in progress

          -  Local or regional local skin lesion

          -  Need of an arthroplasty within the next 12 months

          -  Having received corticosteroids or other molecules in intra-articular infiltration in
             the last 6 months

          -  History of traumatic knee injury (bone injury in the past 24 months), bone, ligament
             or meniscal surgery in the past 24 months

          -  History of disabling peripheral nerve injury

          -  Severe bleeding disorders, anticoagulant treatment in progress or double antiplatelet
             aggregation

          -  BMI &gt; 35 kg/m2

          -  Coxarthrosis with projected knee pain

          -  Pregnant or breastfeeding woman

          -  Patient under guardianship and protection of justice

          -  Allergy/contraindication to botulinum toxin type A, corticoids

          -  Usual contraindication to MRI

          -  Allergy to the contrast product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hichem Khenioui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GHICL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie Lansiaux, MD PhD</last_name>
    <phone>03 20 22 52 69</phone>
    <phone_ext>+33</phone_ext>
    <email>lansiaux.amelie@ghicl.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Sophie Blain</last_name>
    <phone>03 20 22 57 32</phone>
    <phone_ext>+33</phone_ext>
    <email>Blain.Anne-Sophie@ghicl.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lille Catholic University</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>knee</keyword>
  <keyword>Arthrosis</keyword>
  <keyword>Botulinum toxin</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

